Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: A population study

Blood

Volumn 118, Issue 16, 2011, Pages 4331-4337

  Corm, Selim ^a,b   Roche, Laurent ^c,d,e,f   Micol, Jean Baptiste ^a,g   Coiteux, Valérie ^a   Bossard, Nadine ^c,d,e,f   Nicolini, Franck Emmanuel ^h   Iwaz, Jean ^c,d,e,f   Preudhomme, Claude ^a   Roche Lestienne, Catherine ^a   Facon, Thierry ^a   Remontet, Laurent ^c,d,e,f  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER DE CHAMBÉRY   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITÉ LYON 1   (France)

^f CNRS   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SOKAL SCORE; SURVIVAL RATE; SURVIVAL TIME;

EID: 80054833526     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-330332     Document Type: Article

References (18)

1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342-350. (Pubitemid 47094995)
2. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11): 994-1004. (Pubitemid 36302244)
3. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789-799. (Pubitemid 14141296)
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23): 2408-2417. (Pubitemid 44903745)
5. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352(9134):1087-1092. (Pubitemid 28448513)
6. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511-2521.
7. Esteve J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990;9(5):529-538. (Pubitemid 20235022)
8. Remontet L, Bossard N, Belot A, Esteve J. An overall strategy based on regression models to estimate relative survival and model the effects of prognostic factors in cancer survival studies. Stat Med. 2007;26(10):2214-2228. (Pubitemid 46680857)
9. Binquet C, Abrahamowicz M, Astruc K, Faivre J, Bonithon-Kopp C, Quantin C. Flexible statistical models provided new insights into the role of quantitative prognostic factors for mortality in gastric cancer. J Clin Epidemiol. 2009;62(3):232-240.
10. Kantarjian HM, O'Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer. 2003;98(12):2636-2642. (Pubitemid 37509527)
11. Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronicphase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108(5):1478-1484. (Pubitemid 44316111)
12. Brenner H, Gondos A, Pulte D. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008;93(10):1544-1549.
13. Phekoo KJ, Richards MA, Moller H, Schey SA. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006;91(10):1400-1404. (Pubitemid 44569817)
14. Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009; 23(3):602-604.
15. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-years follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054-1061.
16. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24): 2251-2259.
17. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
18. Zaccaria A, Testoni N, Valenti AM, et al. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genet Cytogenet. 2010; 199(2):76-80.